Ad Scientiam Launches Programs to Develop Digital Biomarkers

Ad Scientiam, launches programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis and neuromyelitis optica spectrum disorders

Related Keywords

, Privacy Policy , Ad Scientiam , Digital Biomarkers , Generalized Myasthenia Gravis , Neuromyelitis Optica Spectrum , Ealth Press Release ,